◆ Market Terminal AILook up a stock

Immunovant, Inc. (IMVT)

Healthcare · Biotechnology · Mid-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Immunovant, Inc. is a weaker business by our measures, its shares look expensive compared with other stocks, and its share price has been weak.
Value30
Quality39
Price trend29
Overall32
2633 of 2764rank among the US stocks we score (our core model buys the top 15)
5%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to March 2026, from the company's annual filing with the SEC.

Return on equityprofit vs. shareholders' accounting value-51.3%
Change in share countnegative = the company is buying back its shares+20.4%

Insider trades, last 90 days

3 insiders sold $433K (14% under pre-arranged plans) on the open market.

Pande AtulDirectorSold (plan)Jul 241,500 shat $39.80 · $60K
Girao TiagoChief Financial OfficerSoldJul 236,798 shat $38.69 · $263K
Stout Jay SChief Technology OfficerSoldJul 232,857 shat $38.69 · $111K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy